Market Cap 68.14M
Revenue (ttm) 1.11B
Net Income (ttm) -34.60M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin -3.13%
Debt to Equity Ratio -3.94
Volume 34,000
Avg Vol 31,370
Day's Range N/A - N/A
Shares Out 13.28M
Stochastic %K 63%
Beta 1.78
Analysts Strong Buy
Price Target N/A

Company Profile

INNOVATE Corp., through its subsidiaries, operates in infrastructure, life sciences, and spectrum areas in the United States. The Infrastructure segment provides industrial construction, structural steel, and facility maintenance services, such as fabrication and erection of structural steel and heavy steel plate services, and large-diameter water pipes and water storage tanks; fabrication of trusses and girders; and 3-D building information modeling and detailing for commercial, industrial, and...

Industry: Engineering & Construction
Sector: Industrials
Phone: 212 235 2691
Address:
295 Madison Avenue, 12th Floor, New York, United States
Mister_Hello
Mister_Hello Jun. 19 at 4:51 AM
$VATE Interesting I did not know this name pulled back this much from it's recent highs. Took a look again today. Wonder what happened to bring it back.
0 · Reply
aura66bright9
aura66bright9 May. 28 at 7:25 PM
$VATE Not chasing tomorrow. I’m already in. JFB 💼
0 · Reply
Rohalos
Rohalos May. 23 at 2:08 PM
0 · Reply
GrindTime
GrindTime May. 22 at 7:17 PM
$VATE 20% gain today getting ready.
0 · Reply
stocksutra
stocksutra May. 22 at 5:51 AM
$VATE , Net profit increases by 37%.
0 · Reply
GrindTime
GrindTime May. 12 at 11:42 AM
$VATE in position to pull an RGC move? Only 483 watchers?
0 · Reply
GrindTime
GrindTime May. 8 at 2:53 PM
$VATE can we see over 100 here?
1 · Reply
GrindTime
GrindTime May. 8 at 2:16 PM
$VATE next RGC?
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Apr. 30 at 12:00 PM
$AMIX 🚨🚨2M float to keep on watch!! 🚨🚨 U.S.-based medical device company specializing in technologies for diagnosing and treating diseases involving the peripheral nervous system. 💎Their flagship innovation is a catheter-based microchip sensing array capable of detecting neural signals with up to 3,000 times greater sensitivity than existing technologies. 🧪Autonomix is preparing to initiate U.S. clinical trials for its catheter-based nerve ablation system targeting pancreatic cancer pain. The company has engaged leading medical experts to guide its clinical and regulatory strategies, aiming for FDA De Novo clearance. 📰On April 29, 2025, Maxim Group initiated coverage of Autonomix Medical with a "Buy" recommendation, Here are the levels : 2.60 ➡ 3.09$ ➡ 3.79$ ➡3.94$ ➡4.07$ Website: https://www.autonomix.com/ Disclaimer : https://tinyurl.com/549b47bd #Markets #Investing #StockWatch #Stocks #Investing #StockMarket #Trading #Advertisement $RGLS $VATE $UPLD
0 · Reply
MissHollandia
MissHollandia Apr. 30 at 11:44 AM
$NAYA (IVF ticker, stocktwits didn't change) low float 500K Trump Wants Americans To Have More Babies and Is Willing to Pay $5,000 Each to Make It Happen Premarket movers $RGLS $VATE $NATH
1 · Reply
Latest News on VATE
INNOVATE's Portfolio Company DBM Global to Pay Cash Dividend

May 23, 2025, 4:12 PM EDT - 5 weeks ago

INNOVATE's Portfolio Company DBM Global to Pay Cash Dividend


DBM Global Enters Into an Amended and Restated Credit Agreement

May 20, 2025, 4:06 PM EDT - 5 weeks ago

DBM Global Enters Into an Amended and Restated Credit Agreement


INNOVATE Corp. (VATE) Q1 2025 Earnings Call Transcript

May 6, 2025, 9:02 PM EDT - 7 weeks ago

INNOVATE Corp. (VATE) Q1 2025 Earnings Call Transcript


INNOVATE Corp. Announces First Quarter 2025 Results

May 6, 2025, 4:05 PM EDT - 7 weeks ago

INNOVATE Corp. Announces First Quarter 2025 Results


INNOVATE Corp. to Report First Quarter 2025 Results on May 6th

Apr 16, 2025, 4:05 PM EDT - 2 months ago

INNOVATE Corp. to Report First Quarter 2025 Results on May 6th


INNOVATE Corp. (VATE) Q4 2024 Earnings Call Transcript

Mar 31, 2025, 10:46 PM EDT - 3 months ago

INNOVATE Corp. (VATE) Q4 2024 Earnings Call Transcript


INNOVATE Corp. (VATE) Q3 2024 Earnings Call Transcript

Nov 6, 2024, 10:19 PM EST - 8 months ago

INNOVATE Corp. (VATE) Q3 2024 Earnings Call Transcript


INNOVATE Corp. Announces Third Quarter 2024 Results

Nov 6, 2024, 4:03 PM EST - 8 months ago

INNOVATE Corp. Announces Third Quarter 2024 Results


INNOVATE Corp. (VATE) Q2 2024 Earnings Call Transcript

Aug 7, 2024, 10:09 PM EDT - 11 months ago

INNOVATE Corp. (VATE) Q2 2024 Earnings Call Transcript


INNOVATE Corp. Announces Second Quarter 2024 Results

Aug 7, 2024, 4:04 PM EDT - 11 months ago

INNOVATE Corp. Announces Second Quarter 2024 Results


INNOVATE Corp. (VATE) Q1 2024 Earnings Call Transcript

May 7, 2024, 10:12 PM EDT - 1 year ago

INNOVATE Corp. (VATE) Q1 2024 Earnings Call Transcript


INNOVATE Corp. Announces First Quarter 2024 Results

May 7, 2024, 4:05 PM EDT - 1 year ago

INNOVATE Corp. Announces First Quarter 2024 Results


INNOVATE Corp. Announces Closing of Rights Offering

Apr 24, 2024, 4:47 PM EDT - 1 year ago

INNOVATE Corp. Announces Closing of Rights Offering


INNOVATE Corp. Announces Commencement of Rights Offering

Mar 8, 2024, 9:00 AM EST - 1 year ago

INNOVATE Corp. Announces Commencement of Rights Offering


INNOVATE Corp. Announces Rights Offering Pricing

Mar 6, 2024, 8:00 AM EST - 1 year ago

INNOVATE Corp. Announces Rights Offering Pricing


INNOVATE Corp. (VATE) Q4 2023 Earnings Call Transcript

Mar 4, 2024, 6:10 PM EST - 1 year ago

INNOVATE Corp. (VATE) Q4 2023 Earnings Call Transcript


INNOVATE Corp. Announces Rights Offering for Common Stock

Feb 26, 2024, 8:00 AM EST - 1 year ago

INNOVATE Corp. Announces Rights Offering for Common Stock


INNOVATE Corp. (VATE) Q3 2023 Earnings Call Transcript

Nov 9, 2023, 8:45 PM EST - 1 year ago

INNOVATE Corp. (VATE) Q3 2023 Earnings Call Transcript


INNOVATE Corp. Announces Third Quarter 2023 Results

Nov 9, 2023, 4:05 PM EST - 1 year ago

INNOVATE Corp. Announces Third Quarter 2023 Results


Why Chris DeMuth Jr. Likes Activision, Oil & Gas + Innovate

Aug 22, 2023, 9:20 AM EDT - 2 years ago

Why Chris DeMuth Jr. Likes Activision, Oil & Gas + Innovate

ATVI


INNOVATE Corp. (VATE) Q2 2023 Earnings Call Transcript

Aug 9, 2023, 6:44 PM EDT - 2 years ago

INNOVATE Corp. (VATE) Q2 2023 Earnings Call Transcript


INNOVATE Corp. Names Paul K. Voigt Interim CEO

Jul 25, 2023, 5:04 PM EDT - 2 years ago

INNOVATE Corp. Names Paul K. Voigt Interim CEO


INNOVATE Corp. Announces the Untimely Passing of CEO Wayne Barr

Jul 23, 2023, 4:00 PM EDT - 2 years ago

INNOVATE Corp. Announces the Untimely Passing of CEO Wayne Barr


INNOVATE Corp. (VATE) Q1 2023 Earnings Call Transcript

May 10, 2023, 8:44 PM EDT - 2 years ago

INNOVATE Corp. (VATE) Q1 2023 Earnings Call Transcript


INNOVATE Corp. Announces First Quarter 2023 Results

May 10, 2023, 4:11 PM EDT - 2 years ago

INNOVATE Corp. Announces First Quarter 2023 Results


A New Trade Alert With Chris DeMuth Jr. (Sifting The World)

May 3, 2023, 9:00 AM EDT - 2 years ago

A New Trade Alert With Chris DeMuth Jr. (Sifting The World)

SPB


Mister_Hello
Mister_Hello Jun. 19 at 4:51 AM
$VATE Interesting I did not know this name pulled back this much from it's recent highs. Took a look again today. Wonder what happened to bring it back.
0 · Reply
aura66bright9
aura66bright9 May. 28 at 7:25 PM
$VATE Not chasing tomorrow. I’m already in. JFB 💼
0 · Reply
Rohalos
Rohalos May. 23 at 2:08 PM
0 · Reply
GrindTime
GrindTime May. 22 at 7:17 PM
$VATE 20% gain today getting ready.
0 · Reply
stocksutra
stocksutra May. 22 at 5:51 AM
$VATE , Net profit increases by 37%.
0 · Reply
GrindTime
GrindTime May. 12 at 11:42 AM
$VATE in position to pull an RGC move? Only 483 watchers?
0 · Reply
GrindTime
GrindTime May. 8 at 2:53 PM
$VATE can we see over 100 here?
1 · Reply
GrindTime
GrindTime May. 8 at 2:16 PM
$VATE next RGC?
0 · Reply
TheRealShortSqueezy
TheRealShortSqueezy Apr. 30 at 12:00 PM
$AMIX 🚨🚨2M float to keep on watch!! 🚨🚨 U.S.-based medical device company specializing in technologies for diagnosing and treating diseases involving the peripheral nervous system. 💎Their flagship innovation is a catheter-based microchip sensing array capable of detecting neural signals with up to 3,000 times greater sensitivity than existing technologies. 🧪Autonomix is preparing to initiate U.S. clinical trials for its catheter-based nerve ablation system targeting pancreatic cancer pain. The company has engaged leading medical experts to guide its clinical and regulatory strategies, aiming for FDA De Novo clearance. 📰On April 29, 2025, Maxim Group initiated coverage of Autonomix Medical with a "Buy" recommendation, Here are the levels : 2.60 ➡ 3.09$ ➡ 3.79$ ➡3.94$ ➡4.07$ Website: https://www.autonomix.com/ Disclaimer : https://tinyurl.com/549b47bd #Markets #Investing #StockWatch #Stocks #Investing #StockMarket #Trading #Advertisement $RGLS $VATE $UPLD
0 · Reply
MissHollandia
MissHollandia Apr. 30 at 11:44 AM
$NAYA (IVF ticker, stocktwits didn't change) low float 500K Trump Wants Americans To Have More Babies and Is Willing to Pay $5,000 Each to Make It Happen Premarket movers $RGLS $VATE $NATH
1 · Reply
MissHollandia
MissHollandia Apr. 30 at 9:55 AM
$NAYA nr.1 PREMARKET Trump Wants Americans To Have More Babies and Is Willing to Pay $5,000 Each to Make It Happen $SHMD $FLNT $VATE $UPLD
1 · Reply
MissHollandia
MissHollandia Apr. 30 at 8:55 AM
$VATE PREMARKET MOVERS $NAYA Trump Wants Americans To Have More Babies and Is Willing to Pay $5,000 Each to Make It Happen $UPLD $NATH
0 · Reply
NVSTly
NVSTly Apr. 30 at 8:49 AM
NVSTly Wins Gold Stevie® Award for Tech Startup of the Year in 2025 American Business Awards® https://nvstly.com/blog/NVSTly-Wins-Gold-Stevie-Award-723018 --- Todays watchlist: $TSLA $NVDA $IVF $VATE
0 · Reply
GrindTime
GrindTime Apr. 25 at 12:02 PM
0 · Reply
buyandsold
buyandsold Apr. 10 at 7:27 PM
$VATE the fabrication business will blow up on China tariffs. We wont need medibeacon after the kidney punch of this zeroing, we will need to rely on spectrum as we cancel our cable
0 · Reply
puckbag
puckbag Apr. 2 at 3:02 PM
$VATE "We're making progress on our strategic objectives and our businesses continue to hit important milestones. We continue to believe that we have valuable assets that appreciate in value each day. Our focus is to leverage one or more of these assets prior to reaching the debt maturities in order to achieve sustainable capital structure that allows us to realize the full value of the remaining business."
1 · Reply
GrindTime
GrindTime Apr. 2 at 12:06 PM
$VATE looks like it has a chance back to 50?
0 · Reply
d_risk
d_risk Mar. 31 at 11:58 PM
$VATE - INNOVATE Corp. Common Stock - 10K - Updated Risk Factors VATE's 2025 10-K Risk Factors reveal heightened financial uncertainty with new concerns over going concern viability, tariffs, inflation, and competitive pressures, alongside expanded risks in supply chain, market competition, and financing challenges. #FinancialUncertainty #MarketCompetition #SupplyChain #Inflation #Tariffs 🟢 Added 🟠 Removed https://d-risk.ai/VATE/10-K/2025-03-31
0 · Reply
DonCorleone77
DonCorleone77 Mar. 31 at 8:34 PM
$VATE INNOVATE Corp. reports Q4 EPS ($1.29) vs ($1.22) last year Reports Q4 revenue $236.6M vs. $361M last year...Reports DBM Global grew gross margin to 18.2% in the fourth quarter, an expansion of approximately 180 basis points year-over-year, while Adjusted EBITDA margin decreased to 7.7% in the fourth quarter, a reduction of approximately 80 basis points year-over-year.DBM Global's reported backlog and adjusted backlog, which takes into consideration awarded but not yet signed contracts, was $1.0B and $1.1B , respectively, as of December 31 compared to reported and adjusted backlog of $1.1B and $1.2B respectively, as of December 31, 2023. Subsequent to year end, DBM has added over $500 million to adjusted backlog across our companies and we remain optimistic on the pipeline."We delivered fourth quarter and full year 2024 results largely in-line with our expectations," stated Paul Voigt, INNOVATE's Interim CEO. "We are pleased with the DBM team's disciplined execution, which has resulted in robust margins for 2024 and positioned the business favorably to secure quality projects in 2025. At Life Sciences, FDA approval for MediBeacon's TGFR is a major milestone that we have been anticipating for some time. In addition, two high profile peer-reviewed kidney journals published results from MediBeacon's clinical trials supporting TGFR effectiveness and reinforcing the large unmet medical need. R2 Technologies delivered another strong quarter and expanded its market reach into several new countries. Broadcasting achieved outstanding financial results driven by new quality networks added throughout the year and its fixed cost structure. Lastly, we reduced our total debt by $54.5 million, which is a significant improvement year-over-year."
0 · Reply
mikesterz7
mikesterz7 Mar. 31 at 8:34 PM
$VATE INNOVATE Corp. reported Q4 2024 results with consolidated revenue of $236.6 million, down 34.5% year-over-year. The company posted a net loss of $16.9 million, or $1.29 per share. Key segment performance: Infrastructure: DBM Global revenue decreased 36.2% to $225.7 million, with adjusted backlog of $1.1 billion Life Sciences: MediBeacon received FDA approval for its TGFR kidney function assessment system. R2 Technologies achieved 113% Q4 growth in worldwide system unit sales Spectrum: Broadcasting revenue grew to $6.8 million, up from $5.7 million year-over-year The company reduced total debt by $54.5 million year-over-year. Cash and cash equivalents stood at $48.8 million as of December 31, 2024, compared to $80.8 million the previous year.
0 · Reply
NVDAMillionaire
NVDAMillionaire Mar. 27 at 12:05 PM
$VATE Digging into VATE's financials. Infrastructure segment looks shaky with project completion cycles. Life Sciences might be interesting long-term play. Management exploring strategic alternatives which could unlock value. Keeping position small but watching closely for potential pivot. superb article: https://beyondspx.com/article/innovate-corp-vate-a-diversified-conglomerate-navigating-challenges-and-opportunities
0 · Reply
kharlus
kharlus Mar. 4 at 12:58 PM
$VATE I was lucky on this one. A big learning !! From -15k to breakeven in 40 days… the trade was against me since the day 1. The stock is controlled by one single stakeholder (billionaire family owner of Manchester United fútbol club) and it was very noticeable that the stock was pumped with little volume day after day. That’s was the signal I got to hold my short position. Any day, the trend should be broken … and it was. Anyways, I am not happy with my trade but I got a key learning… never again short a stock where the majority of the shares are hold by a single stakeholder. Good luck all 🤗
0 · Reply